Abstract This study aims to identify the predictive value of cystatin C for diabetic retinopathy (DR) in Chinese patients with type 2 diabetes. Data from a cross-sectional hospitalbased survey of 450 type 2 diabetes patients were analyzed in the study. DR was assessed by fundus fluorescein angiography. Duration of diabetes and other related information were obtained by questionnaire. Body mass index, blood pressure, HbA 1c , cystatin C, glomerular filtration rate, urinary albumin excretion, blood lipids, and uric acid were measured. Binary logistic regression was performed to evaluate potential risk factors for DR. The predictive value of cystatin C for DR was evaluated using ROC curve. Cystatin C (P=0.039) was a risk factor for DR after GFR, and other possibly related variables were adjusted. Cystatin C had a significant predictive value for any DR (AUC, 0.763, P<0.001; optimal cutoff value, 1.11 mg/L; sensitivity, 56.00 %; specificity, 83.90 %) or severe DR (AUC, 0.821, P<0.001; optimal cutoff value, 1.23 mg/L; sensitivity, 73.60 %; specificity, 88.70 %).
Introduction
Diabetic retinopathy (DR) is a severe complication of diabetes and the leading cause of visual loss and blindness in the working aged population [1] . Systematic screening programs for diabetic eye disease have not been established in China, and this increased the danger of DR in patients with diabetes. Increasing evidence shows that traditional risk factors (such as diabetes duration and the control of blood glucose) do not fully explain a patient's risk of having DR [2] , and other undefined risk factors should play important roles in the development of DR. Cystatin C is a small protein that belongs to the cysteine proteinase family and is produced by all nucleated cells at a constant rate. Due to its small size, cystatin C can be filtered by the glomerulus freely, and it is not secreted but is fully reabsorbed and broken down by the renal tubules. This means that the level of blood cystatin C is primarily determined by the glomerular filtration rate (GFR). Studies have found that cystatin C, as a sensitive marker of GFR, is also a sensitive marker to find the early phase of diabetic nephropathy (DN) in patients with diabetes, especially in those diabetic patients with normoalbuminuria [3, 4] . A large number of studies have focused on the relationship between cystatin C and DN, but few studies have analyzed the relationship between cystatin C and DR. A recent study indicated that cystatin C is an independent risk factor for DR, and high cystatin C levels predict sight-threatening DR (STDR) in type 2 diabetes patients [5] . STDR, including severe nonproliferative DR (severe NPDR), proliferative DR (PDR), and clinically significant macular edema (CSME) [6] , greatly contributes to visual loss in patients with diabetes. Systematic screening programs for diabetic eye disease mainly aim to screen for STDR. By means of the screening programs, patients with STDR can be diagnosed early and receive appropriate treatment (for example, laser photocoagulation). This is helpful to protect patient's residual vision and to improve their quality of life. Unfortunately, in many developing countries, including China, the programs have not been developed. If cystatin C was capable of predicting STDR as reported, it could provide a promising predictive parameter to doctors when they suggest that their diabetic patients should visit an ophthalmologist for further professional examination. However, existing epidemiological studies are insufficient for ascertaining the association between cystatin C and DR. DN and DR are microvascular complications of diabetes, and they have similar pathogenesis and risk factors. There is a close association between DN and DR, and the occurrence of DN probably predicts the existence of DR. As an important characteristic of DN, the decline of GFR should be associated with DR. One study also found that lower estimated GFR was significantly associated with the severity of DR in Chinese patients with type 2 diabetes mellitus [7] . If there was a close association between cystatin C and DR, it is reasonable to speculate that the association is probably only because cystain C is a sensitive marker for the estimation of GFR. Therefore, three problems are not clear and are worth exploring. First, it is not clear whether cystatin C is a real risk factor for DR. Second, it is not clear whether cystatin C has any value in predicting DR. Third, it is not clear whether or not the effect of cystatin C on DR is dependent on GFR. The aims of this study were to further evaluate the effect of cystatin C on DR and to identify the predictive value of cystatin C for DR, as well as to evaluate whether the effect of cystatin C on DR is independent of GFR.
Materials and methods

Subject selection
Four hundred and fifty patients with type 2 diabetes were recruited from the Diabetes Centre of Dezhou People's Hospital from January 2012 to December 2013. Type 2 diabetes mellitus was diagnosed according to the 1999 World Health Organization criteria. The exclusion criteria of study subjects were as follows: (1) type 1 diabetes; (2) specific type diabetes or gestational diabetes mellitus; (3) with acute complications of diabetes (such as infection or diabetic ketoacidosis); (4) with serious hepatic disease; (5) with acute or serious cardiovascular disease; (6) trauma or other definite causes and secondary nephropathy (such as glomerular nephritis, pyelonephritis, nephrolithiasis, or lupus nephritis); (7) retinopathy caused by hypertension; (8) with contraindications to fundus fluorescein angiography (FFA); and (9) with contraindications to perform 99m Tc-DTPA dynamic renal imaging. The study was approved by the Human Research and Ethics Committee of Dezhou People's Hospital, and all participants signed informed consents that adhered to the tenets of the declaration of Helsinki.
Data collection and measurements
Information on gender, age, duration of diabetes, family history of diabetes, history of smoking, and history of hypertension were obtained using a questionnaire. According to fundus fluorescein angiography (FFA) examination, patients were classified as follows: no DR (NDR); mild nonproliferative DR (mild NPDR); moderate nonproliferative DR (moderate NPDR); and severe DR, including severe NPDR or PDR [8] . Blood pressure was measured. Hypertension was defined as systolic blood pressure (SBP) ≥140 mmHg, diastolic blood pressure (DBP) ≥90 mmHg, or with definite history of hypertension. Weight and height were measured, and body mass index (BMI) was calculated by equation [BMI = weight/ height/height (kg/m 2 )]. Venous blood samples were drawn from all patients after an overnight fast. The concentration of serum cystatin C was measured by a highly sensitive latexenhanced immunoturbidimetric method. GFR was assessed using 99m Tc-diethylene triamine pentaacetic acid (DTPA) dynamic renal imaging (Gates method). High pressure liquid chromatography method was performed to measure glycosylated hemoglobin (HbA 1c ). Total cholesterol (TC) and triglyceride (TG) were measured by an enzyme-coupling colorimetric method. High-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) were measured by a direct method. An immunoturbidimetric method was used to measure apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB), and urinary albumin excretion (UAE). Uric acid (UA) was measured by uricase method. The ratio of AopA1/ ApoB was calculated.
Statistical analysis
Statistical analysis was performed by using a commercially available statistical software package (SPSS for Windows, version 16.0, SPSS, Chicago). Continuous variables were tested for normal distribution by the Kolmogorov-Smirnov test. The normal distributed continuous variables are described as the mean±SD, and those nonparametrically distributed are shown as the median (interquartile range). Discrete variables are presented as frequencies (percentages). Comparisons of the groups for normally distributed continuous variables were p e r f o r m e d b y t t e s t o r o n e -w a y A N O VA . F o r nonparametrically distributed continuous variables, nonparametric test was used. The comparison of discrete variables was performed by the Chi-square test (R×C tables). Binary logistic regression was performed to evaluate the risk factors of DR. The variables that were proven to be significant in the univariate analysis were entered (method: forward: LR) as independent variables in the regression model. Bivariate correlation analysis of Spearman was performed to evaluate the correlation between cystatin C and the severity level of DR. The ability of cystain C in predicting DR was evaluated using a receiver operating characteristic (ROC) curve. All P values were two-sided, and a P<0.05 was considered statistically significant.
Results
General information
Four hundred and fifty patients including 267 males (59.33 %) and 183 females (40.67 %) were involved in this study. The mean age was 55.17 ± 10.32 years old, and the median (interquartile) duration of diabetes was 6.00 years (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . Of the 450 patients, 60 (13.33 %) had mild NPDR, 51 (11.33 %) had moderate NPDR, 39 (8.67 %) had severe NPDR, and 21 (4.67 %) had PDR. The prevalence of DR was 38.00 %.
Analysis of risk factors for DR
Between patients with and without DR, there were significant differences in age, duration of diabetes, hypertension, SBP, HbA 1c , Cystatin C, GFR, UAE, and AopA1/ApoB (all P<0.01; Table 1 ). Of these variables, duration of diabetes, HbA 1c , cystatin C, hypertension, GFR, and ApoA1/ApoB retained their significant associations with the presence of DR in the binary logistic regression model (P<0.05; Table 2 ).
Association between cystatin C and severity levels of DR
The serum concentration of cystatin C was significantly different among patients with different severity levels of DR (F= 12.667, P<0.001), and an increasing tendency of the concentration of cystatin C was shown with the increase in the severity level of DR (Fig. 1 ). There was a positive correlation between cystatin C and the severity level of DR (Spearman r= 0.534, P<0.001; Table 3 ).
Analysis of value for cystatin C in predicting DR
Cystatin C had significant value (AUC, 0.763, P<0.001; 95 % CI, 0.681-0.846) in predicting DR (Fig. 2) . The optimal cutoff NDR no diabetic retinopathy, DR diabetic retinopathy, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, HbA 1c glycosylated hemoglobin, UA uric acid, GFR glomerular filtration rate, UAE urinary albumin excretion, TC total cholesterol, TG triglyceride, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, ApoA1 apolipoprotein A1, ApoB apolipoprotein B (Fig. 3) .
Discussion
This study found that cystatin C was a risk factor for DR after GFR and other potentially related variables were adjusted. The result indicates that the effect of cystatin C on DR is independent of GFR. Since cystatin C is a sensitive marker of GFR, we could speculate that the close association between cystatin C and DR does not depend on the excellent ability of cystatin C for the estimation of GFR. However, why there is a close association between cystatin C and DR is not clear. The pathophysiologic changes of DR include edema of the macula, retinal inflammation, neovascularization, and optic neuropathy [9] [10] [11] [12] , and cystatin C likely plays an important role in these pathophysiologic changes. Retinal pigment epithelium (RPE) was identified as a major site for secretion of cystatin C, which is involved in the mechanisms of macular degeneration [13] . The neuroretina was found to be a high-affinity system, and human cystatin C injected intravitreally into normal rat eyes can be taken up into cells of the neuroretina and into the retinal pigment [14] . We speculate that there is perhaps a similar system in humans through which higher serum cystatin C could be taken up into the retinal pigment. Cystatin C plays an important role in inflammation and increases the levels of Creactive protein (CPR) [15] and homocysteine (Hcy) [16] , which is involved in the impairment of the microvasculature. Cystatin C is also speculated to be involved in arterial wall remodeling, blood vessel integrity, neovascularization, and neuronal degenerative pathology [17] . These mechanisms mentioned above, involving cystatin C and DR, might partly explain the close association between them. Our findings indicate that cystatin C is a novel risk factor for DR, which probably partly solves the question why traditional risk factors do not fully explain a patient's risk of having DR. The study found that there was a significant value for cystatin C in predicting any DR. However, the optimal cutoff value (1.11 mg/L) is not ideal. Despite the higher specificity (83.90 %), the sensitivity (56.00 %) is lower. In our study, cystatin C had a more ideal cutoff point in predicting severe DR. Sensitivity and specificity were 73.60 and 88.70 %, respectively, when the optimal cutoff point was 1.23 mg/L. This indicates that cystatin C seems to be a better predictive marker for severe DR, and higher cystatin C levels are more capable of discriminating severe DR in patients with type 2 diabetes mellitus. This study found that cystatin C significantly correlated with the severity level of DR, and this probably explains why the ability of cystatin C in predicting severe DR was superior to its ability in predicting any DR. DR, especially Fig. 1 Cystatin C in patients with NDR, mild NPDR, moderate NPDR, and severe DR. a Compared with moderate NPDR (P=0.012), mild NPDR (P = 0.001), or NDR (P < 0.001), there were significant differences; b compared with NDR (P=0.017), there was a significant difference. NDR no diabetic retinopathy, mild NPDR mild nonproliferative diabetic retinopathy, moderate NPDR moderate nonproliferative diabetic retinopathy, severe NPDR severe nonproliferative diabetic retinopathy, PDR proliferative diabetic retinopathy severe DR, can result in severe and irreversible visual loss. Except for common treatments (such as strict control of blood glucose and blood pressure and lipids), laser photocoagulation is the first and most effective option for treatment for DR. The Early Treatment Diabetic Retinopathy Study (ETDRS) showed that laser photocoagulation can reduce the progression of DR [18] and the risk of vision loss from PDR [19] . ETDRS also examined the effect of treating eyes with mild NPDR to early PDR and suggested that scattered photocoagulation could be deferred at the stage of mild-to-moderate NPDR because the rate of visual loss was low with either treatment of photocoagulation applied early or delayed. When DR is more severe, photocoagulation should not be delayed. Therefore, early diagnosis of severe DR is very important for initiating effective laser photocoagulation. However, systematic screening programs for DR have not been developed in many developing and poor countries (including China). Many diabetic patients with severe DR cannot be diagnosed in time, and so, they do not undergo timely and effective treatment (especially laser photocoagulation). This results in the progression of visual loss, and even blindness. In fact, most of the patients with diabetes always visit an endocrinologist, but not an ophthalmologist unless their eyes have significant visual abnormality. Therefore, it is critical that endocrinologists suggest that their patients visit an ophthalmologist to find existing DR, especially severe DR. It is helpful for those patients with severe DR to avoid further visual loss by means of the early diagnosis and appropriate initiation of photocoagulation. According to the optimal cutoff point of cystatin C in predicting severe DR, a concrete predictive index should be provided to endocrinologists when they suggest that their patients with type 2 diabetes visit an ophthalmologist for further professional examination. Moreover, the measurement of cystatin C is more convenient and economical than retinal photographs. Considering the growing financial burden of diabetes, cystatin C may be a promising biomarker in screening and forecasting the presence of severe DR. Our study found that GFR is a protective factor for DR. The decrease of GFR is characteristic of diabetic nephropathy, and loss of GFR often occurs before the onset of microalbuminuria in type 2 diabetes mellitus [20] . Most previous studies only used albuminuria as a criterion to evaluate the existence of DN, which probably underestimated the association between DN with DR. Our study also found that the ratio of ApoA1/ ApoB is also a protective factor for DR. Recently, several studies revealed that ApoA1, ApoB, ApoA1/ApoB, or ApoB/ApoA1 were significantly associated with DR [21] [22] [23] . Our study further demonstrates that ApoA1/ApoB should play very important role in the progression of DR. Interestingly, no significant difference was found between the patients with and without DR regarding ApoA1 or ApoB, which indicates that ApoA1/ApoB is probably more important than ApoA1 or ApoB alone in the progression of DR. TG, TC, HDL-C, or LDL-C did not show any significant differences between patients with and without DR in our study, which indicates that ApoA1/ApoB is probably more important than these lipid constituents in the progression of DR.
It is well known that duration of diabetes, the control of glucose, and blood pressure are the traditional risk factors for DR [24] . Our study also found that duration of diabetes, HbA 1c , and hypertension were significantly associated with Age, UAE, and SBP were significantly different between patients with DR and patients without DR in the univariate analysis. However, those variables were not included in the binary logistic regression model. It has been known that duration of diabetes is the strongest risk factor of DR, and there is a very close association between age and duration. For a patient with DR, whose duration of DR must be increased with the increase of age. Age should be not in the analysis model as a confounded factor when duration of DR was taken as an independent variable in the regression model. We also found that hypertension was significantly associated with DR. However, SBP was not included in the binary logistic regression model. I think that the influence of treatment of antihypertensive drugs should be the possible cause. Some studies indicated that UAE was associated with DR. However, UAE could not be included in the binary logistic regression model in our study. In fact, many studies that explored the association between UAE and DR did not take GFR as an independent variable into logistic regression model; this perhaps resulted in their analysis were different from us. It has been known that UAE is the important characteristic of DN, and there is a close association between DN and DR. In matter of fact, GFR is more sensitive marker for detecting of DN than UAE. In some patients with DN, UAE was normal but GFR has been decreased. Generally, we believed that the association between UAE and DR was based on the close association between DN and DR. Once GFR was taken as an independent variable into logistic regression model, the influence of UAE for DR should be weakened, and UAE turned into a confounded factor.
One advantage of this study was the rigorous inclusion criteria of subjects, which decreased the disturbance of some related confounding factors. However, Gate method is a limitation. It has been known that 99m Tc-DTPA plasma clearance (two sample method) is the recommended method to measure GFR by international society of nuclear medicine. Despite studies indicated that there was a high relation between Gates method and two sample method, the limitation of the Gates methods is obvious. Some studies indicated that Gates method possibly overestimated GFR of patients with severe renal disfunction. Fortunately, the number of severe renal disfunction of patients with T2DM that participated in our study was scarce, and this possibly weakened the limitation of Gates method. Additionally, the single source of study subjects is a limitation. Subjects of this study only came from one diabetes center, which perhaps resulted in the number of severe DR (especially PDR) being less because many patients with severe DR visited the department of ophthalmology. This probably underestimated the association between cystatin C and DR. More epidemiologic (especially multicenter studies and prospective studies) and pathophysiological studies should be designed so that the association of cystatin C with DR can be confirmed.
Conclusion
Cystatin C is a novel risk factor for DR, and cystatin C should be used to screen and forecast the presence of DR (especially severe DR) in Chinese patients with type 2 diabetes. The association between cystiatin C and DR should not depend on the excellent ability of cystatin C for the estimation of GFR.
